<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223158</url>
  </required_header>
  <id_info>
    <org_study_id>CRC 03-52-R1</org_study_id>
    <nct_id>NCT00223158</nct_id>
  </id_info>
  <brief_title>Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer</brief_title>
  <official_title>L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrice Perron</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theramed co.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <brief_summary>
    <textblock>
      To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo
      or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy. To evaluate the
      time needed for TSH elevation (&gt; 30 mUI/L) on placebo vs. L-T3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with well differentiated thyroid cancer (DTC) need whole-body scintigraphy (WBS) and
      thyroglobulin (Tg) measurement in order to detect recurrence. Classically, withdrawal from
      levothyroxine (L-T4) during 4-6 weeks is needed for TSH elevation (&gt; 30mUI/L), to allow
      iodine uptake and Tg production. As a result, patients become hypothyroid with impaired
      quality of life and a potential for tumour flare-up. Recombinant hTSH before WBS prevents
      hypothyroidism but is not yet approved for radioiodine treatment and is an expensive therapy.
      L-T3 substitution during the first 2-3 weeks of withdrawal is an alternative used empirically
      to prepare patients; however, no data exists to prove its benefit upon reducing
      hypothyroidism.

      Objectives: 1) To compare the hypothyroid state in patients prepared either by placebo or
      L-T3 following L-T4 withdrawal. 2) To evaluate the time needed for TSH elevation (&gt; 30 mUI/L)
      on placebo vs. L-T3.

      Method: At the time of L-T4 withdrawal or after thyroidectomy, patients with DTC awaiting WBS
      or radioiodine treatment were randomized in two groups (double-blind): L-T3 (50 mg qd) or an
      identical placebo for 3 weeks, after which treatment was stopped for 2 weeks. A validated
      questionnaire of signs and symptoms of hypothyroidism (Billewicz's scale) was administered
      every 2 weeks until the WBS. TSH, fT4 and fT3 were measured weekly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the hypothyroid status by the Billewicz questionnaire.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to reach an acceptable TSH elevation.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Thyroid Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with well-differentiated thyroid cancer, with total thyroidectomy

          -  18 y.o. or older

        Exclusion Criteria:

          -  Use of rhTSH for Whole Body Scintigraphy preparation

          -  Non stable cardiac arrythmias

          -  Any condition impairing TSH elevation(glucocorticoid use, hypopituitarism)

          -  Allergy to Liothyronine

          -  Inability to give a consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rébecca Leboeuf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-France Langlois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Perron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Carpentier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Verreault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Patrice Perron</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Thyroid cancer</keyword>
  <keyword>Hypothyroidism</keyword>
  <keyword>Whole Body Scintigraphy</keyword>
  <keyword>Liothyronine</keyword>
  <keyword>TSH elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

